Table 5 Effects of metformin on ventricular arrhythmias: reports from clinical trials
From: Effects of metformin on atrial and ventricular arrhythmias: evidence from cell to patient
| Model | Type of study/No. of patients/FU | Metformin (dose/duration) | Key results and major findings | Interpretation | References |
|---|---|---|---|---|---|
|
DM patients with CAD monitored via 24-h Holter monitor (mean age 55) | Randomized crossover design/19 patients/2 weeks | Metformin 500 mg BID for 2 weeks | - <-> PVC/NSVT per minute of ischemia | Metformin did not reduce PVC/NSVT in diabetic CAD patients | [94] |
|
Hospitalized DM patients with AMI (mean age 56) | Retrospective cohort/40 Metformin alone and 705 others/28-day post AMI | Various doses | - <-> 28-days VT/VF incidence | Metformin alone or in combination with other anti-DM drugs was not associated with decreased 28-day post AMI VT/VF incidence | [56] |